Sclerostin Rather Than Dickkopf-1 is Associated with MSASSS but Not with Disease Activity Score in Patients with Ankylosing Spondylitis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2018 Nov 17

PMID 30443790

Citations 10

Authors

Wenjia Sun

Lizhen Tian

Lichun Jiang

Songzhao Zhang

Meiju Zhou

Jianing Zhu

Jing Xue

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the serum levels of Dickkopf-1 (DKK-1) and sclerostin, as well as their correlations with the structural damage assessed by modified stoke ankylosing spondylitis spine score (mSASSS) and the disease activity evaluated by ankylosing spondylitis disease activity score (ASDAS) in patients with ankylosing spondylitis (AS).

Methods: Eighty-eight AS patients, 26 rheumatoid arthritis (RA) patients, and 26 age- and gender-matched healthy controls (HC) were collected from rheumatic clinic of the Second Affiliated Hospital of Zhejiang University, School of Medicine, between March 2015 and July 2015. Demographic data, parameters of ASDAS, and image evaluations of spine (i.e., mSASSS) were collected. The serum levels of DKK-1 and sclerostin were measured using commercially available ELISA kits.

Results: Both DKK-1 and sclerostin were significantly higher in the AS patients than in the controls (1855 ± 84.58 vs. 1406 ± 99.76 pg/ml and 106 ± 6.75 vs. 62.78 ± 6.39 pmol/l, respectively, P < 0.05). The correlation analysis suggested a negative correlation between serum sclerostin and mSASSS (P = 0.019, r = 0.062). DKK-1 had a trend of positive correlation with mSASSS, but was not statistically significant (P > 0.05). There was no association between the serum levels of DKK-1 or sclerostin and disease activity assessed by ASDAS (P > 0.05). DKK-1 and sclerostin had a negative correlation (P = 0.013, r = 0.07).

Conclusion: In the present study, the expressions of serum DKK-1 and sclerostin were independent of disease activity. Sclerostin was negatively correlated with the mSASSS, which suggests that sclerostin may be a potential marker indicating the spine ossification process in AS. The specific mechanism remains to be investigated.

Citing Articles

The serum level of sclerostin decreases in radiographic axial spondyloarthritis patients with fatty lesions.

Li X, Jiang H, Wang X, Zhong S Arthritis Res Ther. 2025; 27(1):10.

PMID: 39825398 PMC: 11740347. DOI: 10.1186/s13075-025-03479-x.

A guideline on biomarkers in the diagnosis and evaluation in axial spondyloarthritis.

Liu D, Xie Y, Tu L, Wen X, Lv Q, Liu B Front Immunol. 2024; 15:1394148.

PMID: 39539543 PMC: 11557325. DOI: 10.3389/fimmu.2024.1394148.

The Role of Sclerostin in Rheumatic Diseases: A Review.

Jaskiewicz L, Chmielewski G, Kuna J, Stompor T, Krajewska-Wlodarczyk M J Clin Med. 2023; 12(19).

PMID: 37834893 PMC: 10573925. DOI: 10.3390/jcm12196248.

Serum concentration of dickkopf-related protein 1 (DKK1) in psoriatic arthritis in the context of bone remodelling.

Biedron G, Czepiel M, Siedlar M, Korkosz M Rheumatol Int. 2023; 43(12):2175-2183.

PMID: 37750896 PMC: 10587027. DOI: 10.1007/s00296-023-05452-w.

Serum DKK-1 level in ankylosing spondylitis: insights from meta-analysis and Mendelian randomization.

Fang X, Chen C, Wang Z, Zhao Y, Jiang L, Fang Y Front Immunol. 2023; 14:1193357.

PMID: 37503346 PMC: 10368999. DOI: 10.3389/fimmu.2023.1193357.

References

Klavdianou K, Liossis S, Sakkas L, Daoussis D . The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma?. Semin Arthritis Rheum. 2016; 46(4):430-438. DOI: 10.1016/j.semarthrit.2016.08.014. View

MacDonald B, Tamai K, He X . Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1):9-26. PMC: 2861485. DOI: 10.1016/j.devcel.2009.06.016. View

Xie W, Zhou L, Li S, Hui T, Chen D . Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci. 2015; 1364:25-31. PMC: 4803629. DOI: 10.1111/nyas.12968. View

Chou C . How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis. Clin Dev Immunol. 2013; 2013:369202. PMC: 3693102. DOI: 10.1155/2013/369202. View

Muntean L, Lungu A, Gheorghe S, Valeanu M, Craciun A, Felea I . Elevated Serum Levels of Sclerostin are Associated with High Disease Activity and Functional Impairment in Patients with Axial Spondyloarthritis. Clin Lab. 2016; 62(4):589-97. DOI: 10.7754/clin.lab.2015.150801. View

Yucong Z, Lu L, Shengfa L, Yongliang Y, Ruguo S, Yikai L . Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin Lab. 2014; 60(9):1527-31. DOI: 10.7754/clin.lab.2014.131119. View

Costa A, Cremers S, Bilezikian J . Sclerostin measurement in human disease: Validity and current limitations. Bone. 2016; 96:24-28. DOI: 10.1016/j.bone.2016.10.012. View

Tsui F, Tsui H, Las Heras F, Pritzker K, Inman R . Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis. 2013; 73(10):1873-9. DOI: 10.1136/annrheumdis-2013-203630. View

Zhou Y, Wang T, Hamilton J, Chen D . Wnt/β-catenin Signaling in Osteoarthritis and in Other Forms of Arthritis. Curr Rheumatol Rep. 2017; 19(9):53. PMC: 5672801. DOI: 10.1007/s11926-017-0679-z. View

10.

Corr M . Wnt signaling in ankylosing spondylitis. Clin Rheumatol. 2014; 33(6):759-62. DOI: 10.1007/s10067-014-2663-6. View

11.

Ustun N, Tok F, Kalyoncu U, Motor S, Yuksel R, Yagiz A . Sclerostin and Dkk-1 in patients with ankylosing spondylitis. Acta Reumatol Port. 2014; 39(2):146-51. View

12.

Kwon S, Lim M, Suh C, Park S, Hong Y, Yoon B . Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int. 2011; 32(8):2523-7. DOI: 10.1007/s00296-011-1981-0. View

13.

Klavdianou K, Liossis S, Papachristou D, Theocharis G, Sirinian C, Kottorou A . Decreased Serotonin Levels and Serotonin-Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis. J Bone Miner Res. 2015; 31(3):630-9. DOI: 10.1002/jbmr.2724. View

14.

Korkosz M, Gasowski J, Leszczynski P, Pawlak-Bus K, Jeka S, Kucharska E . High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord. 2013; 14:99. PMC: 3639156. DOI: 10.1186/1471-2474-14-99. View

15.

Ke H, Richards W, Li X, Ominsky M . Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012; 33(5):747-83. DOI: 10.1210/er.2011-1060. View

16.

Daoussis D, Andonopoulos A, Liossis S . Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum. 2008; 39(5):369-83. DOI: 10.1016/j.semarthrit.2008.10.008. View

17.

Machado P, Landewe R, van der Heijde D . Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018; 77(10):1539-1540. DOI: 10.1136/annrheumdis-2018-213184. View

18.

Heiland G, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H . High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2011; 71(4):572-4. DOI: 10.1136/annrheumdis-2011-200216. View

19.

Braun J, Sieper J . Ankylosing spondylitis. Lancet. 2007; 369(9570):1379-1390. DOI: 10.1016/S0140-6736(07)60635-7. View

20.

Osman M, Maksymowych W . An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis. Expert Rev Clin Immunol. 2016; 13(2):125-131. DOI: 10.1080/1744666X.2016.1218761. View